Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment
Sponsor: St. Paul's Sinus Centre
Summary
This study aims to analyze the immune profiles of patients with Chronic Rhinosinusitis with Nasal polyps (CRSwNP) with and without asthma before and after Mepolizumab. A group of participants with CRS without nasal polyps (CRSsNP) with asthma will be included to compare their immune profiles to CRSwNP.
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2023-07-01
Completion Date
2025-06-30
Last Updated
2024-04-17
Healthy Volunteers
No
Interventions
Mepolizumab
Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
Placebo
Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
Locations (1)
St. Pual's Sinus Centre
Vancouver, British Columbia, Canada